The Future Of Aseptic Connections In Cell And Gene Therapies

In a market where efficiencies, cost savings, repeatable processes and safety are vital, cell and gene therapy companies must routinely evaluate their processes and analyze where improvements can be made, even down to the way they are managing fluid transfer.

Originally presented live on July 19th and July 21st, CPC's Application Development Manager, Ray Rendon, examines open small format tubing in cell and gene therapy labs – and what technologies are on the horizon to help make more sterile connections going forward. He discussed the total cost of ownership of tube welded connections and single-use aseptic connectors and reviews vital evaluating criteria such capital expenditure, raw materials and utilities, but also dives deeper into considerations such as training, downtime, validations, and connection speed.